Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Jazz Pharmaceuticals plc

NASDAQ: JAZZ · Life Sciences · 12 alerts · CIK 1232524

Share price
$239.77Close, Nov 16
Market cap
$15.4B
Shares outstanding
64.19MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Jazz Pharmaceuticals plc filings on SEC EDGAR ↗

4:46 PM ET Form 4
Insider Selling

Jazz Pharmaceuticals Insider Bruce C. Cozadd Sells $16.2M of Stock

Bruce C. Cozadd sold 68,808 shares of Jazz Pharmaceuticals plc at $234.91 to $237.39 a share (average $235.95) in 4 transactions, worth $16.2M in total on Nov 6, 2026. Shares held after the trade: 357,567 (-1.6%).

Value
$16.2M
Shares
68,808
Average price
$235.95
Holding change
-1.6%
Trade date
Nov 6, 2026
5:20 PM ET Form 4
Insider Selling

Jazz Pharmaceuticals SVP, CAO Patricia Carr Sells $327K of Stock

Patricia Carr, SVP, CAO, sold 1,413 shares of Jazz Pharmaceuticals plc at $231.27 to $231.37 a share (average $231.36) in 2 transactions, worth $327K in total on Nov 4, 2026. Shares held after the trade: 6,512 (-2.4%).

Value
$327K
Shares
1,413
Average price
$231.36
Role
SVP, CAO
Holding change
-2.4%
Trade date
Nov 4, 2026
6:29 PM ET Form 4
Insider Selling

Jazz Pharmaceuticals President & CEO Renee D. Gala Sells $225K of Stock

Renee D. Gala, President & CEO, sold 1,000 shares of Jazz Pharmaceuticals plc at $225.37 a share, worth $225K in total on Nov 3, 2026. Shares held after the trade: 140,394 (-0.7%).

Value
$225K
Shares
1,000
Price
$225.37
Role
President & CEO
Holding change
-0.7%
Trade date
Nov 3, 2026
6:35 PM ET Form 4
Insider Selling

Jazz Pharmaceuticals Insider Bruce C. Cozadd Sells $1.3M of Stock

Bruce C. Cozadd sold 6,000 shares of Jazz Pharmaceuticals plc at $215.84 a share, worth $1.3M in total on Nov 2, 2026. Shares held after the trade: 339,875 (-1.7%).

Value
$1.3M
Shares
6,000
Price
$215.84
Holding change
-1.7%
Trade date
Nov 2, 2026
4:08 PM ET 8-K
Financial Results

Jazz Pharmaceuticals Financial Results

Jazz Pharmaceuticals reported record third-quarter 2026 revenues of $1.2 billion, a 10% increase year-over-year, driven by strong performance from Xywav and the launch of Ziihera. The company raised its full-year 2026 revenue guidance to a range of $4.775 billion to $4.85 billion and highlighted the closing of its acquisition of Actio Biosciences.

“Our third-quarter performance reflects sustained execution across the business and gives us confidence to raise our full-year total revenue guidance. At the same time, we continue to strengthen the drivers of our future growth, with the approval and rapid launch of Ziihera in first-line HER2-positive GEA and the acquisition of Actio, which adds ABS-1230 and deepens our pipeline in rare, refractory epilepsies. Jazz is moving with momentum and urgency to advance practice-changing medicines that deliver meaningful benefit for patients and durable value for shareholders.”

Renee Gala, president and chief executive officer of Jazz Pharmaceuticals
4:03 PM ET 8-K
Business Update

Jazz Pharmaceuticals Business Update

Jazz Pharmaceuticals provided a preliminary update on its Q3 2026 financial results, estimating a $755 million pre-tax charge for acquired in-process research and development (IPR&D) related to its acquisition of Actio Biosciences. This non-deductible charge is expected to have an unfavorable impact of approximately $11.00 on both GAAP and non-GAAP adjusted earnings per share for the quarter.

Counterparty
Actio Biosciences, Inc.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.